JP2021504349A - チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物 - Google Patents

チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物 Download PDF

Info

Publication number
JP2021504349A
JP2021504349A JP2020528252A JP2020528252A JP2021504349A JP 2021504349 A JP2021504349 A JP 2021504349A JP 2020528252 A JP2020528252 A JP 2020528252A JP 2020528252 A JP2020528252 A JP 2020528252A JP 2021504349 A JP2021504349 A JP 2021504349A
Authority
JP
Japan
Prior art keywords
thymosin
mucin
composition according
composition
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020528252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504349A5 (enExample
Inventor
カン・シンウク
キム・ギョンスン
ヤン・ウォンソク
ソン・ジヘ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HLB Therapeutics Co Ltd
Original Assignee
G TreeBNT Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G TreeBNT Co Ltd filed Critical G TreeBNT Co Ltd
Publication of JP2021504349A publication Critical patent/JP2021504349A/ja
Publication of JP2021504349A5 publication Critical patent/JP2021504349A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2020528252A 2017-11-24 2018-11-23 チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物 Pending JP2021504349A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762590444P 2017-11-24 2017-11-24
US62/590,444 2017-11-24
PCT/KR2018/014522 WO2019103523A2 (ko) 2017-11-24 2018-11-23 티모신 베타 4 또는 이의 유도체를 유효성분으로 포함하는 술잔세포 증식 또는 뮤신 분비 촉진용 조성물

Publications (2)

Publication Number Publication Date
JP2021504349A true JP2021504349A (ja) 2021-02-15
JP2021504349A5 JP2021504349A5 (enExample) 2021-12-23

Family

ID=66630753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020528252A Pending JP2021504349A (ja) 2017-11-24 2018-11-23 チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物

Country Status (8)

Country Link
US (1) US20200353052A1 (enExample)
EP (1) EP3715451A4 (enExample)
JP (1) JP2021504349A (enExample)
KR (1) KR20200081402A (enExample)
CN (1) CN111386337A (enExample)
AU (1) AU2018372396A1 (enExample)
CA (1) CA3083101A1 (enExample)
WO (1) WO2019103523A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023027B (zh) * 2020-07-21 2023-03-14 广东海洋大学 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物
CN111888463B (zh) * 2020-08-18 2021-09-21 华中农业大学 用于治疗抑郁症的胸腺素β4药物制剂与制备方法及其应用
WO2024233903A1 (en) * 2023-05-11 2024-11-14 Wayne State University Combination treatments to promote epithelial integrity and treat ocular disorders
KR20250098014A (ko) * 2023-12-21 2025-07-01 주식회사 비제이와이 탈모 예방 또는 발모 촉진용 흉선 유래 펩타이드 유도체 및 이의 이용

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506293A (ja) * 2001-03-15 2005-03-03 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法
CN106692949A (zh) * 2016-12-23 2017-05-24 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
JP2017533262A (ja) * 2014-10-22 2017-11-09 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032392A (en) * 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US20110020449A1 (en) * 1998-07-30 2011-01-27 Regenerx Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
WO2003086449A1 (en) * 2002-04-12 2003-10-23 Yale University ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN β 4
US20090131313A1 (en) * 2005-06-17 2009-05-21 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods for treating or preventing tissue deterioration, injury or damage
CN1896096A (zh) * 2005-07-15 2007-01-17 北京诺思兰德生物技术有限责任公司 基因工程方法生产的高活性胸腺素β4衍生物
CN100484957C (zh) * 2005-09-23 2009-05-06 北京诺思兰德生物技术股份有限公司 胸腺素β4衍生物及其应用
WO2009033814A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
US9504730B2 (en) * 2010-09-30 2016-11-29 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
KR20160047321A (ko) * 2014-10-22 2016-05-02 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 조성물
KR102340750B1 (ko) * 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506293A (ja) * 2001-03-15 2005-03-03 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド サイモシンβ４（Ｔβ４）、類似体、アイソホーム、および他の誘導体を用いて眼および周辺組織の疾患を治療するための方法
JP2017533262A (ja) * 2014-10-22 2017-11-09 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤
CN106692949A (zh) * 2016-12-23 2017-05-24 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EXPRT OPIN. BIOL. THER., vol. Vol. 15, Suppl. 1, JPN6022041532, 2015, pages 155 - 161, ISSN: 0005044963 *

Also Published As

Publication number Publication date
AU2018372396A1 (en) 2020-06-25
CA3083101A1 (en) 2019-05-31
EP3715451A2 (en) 2020-09-30
KR20200081402A (ko) 2020-07-07
WO2019103523A2 (ko) 2019-05-31
WO2019103523A3 (ko) 2019-07-18
EP3715451A4 (en) 2021-07-21
US20200353052A1 (en) 2020-11-12
CN111386337A (zh) 2020-07-07

Similar Documents

Publication Publication Date Title
JP3058920B2 (ja) アルブミンを有効成分とする医薬組成物
JP2021504349A (ja) チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物
JP7081850B2 (ja) 眼科用製剤
US12064469B2 (en) Stable peptide compositions
IL218504A (en) Use of lkktet and / or lkktnt peptides to treat dry eye syndrome
US11419880B2 (en) Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
JP2019533722A (ja) Ｐｅｄｆ由来短ペプチドを含む組成物およびその使用
JP2020183391A (ja) チモシンベータ４を含む眼科用製剤の製造方法
EP4342452A1 (en) Eye drop composition comprising recoflavone for treatment of xerophthalmia
AU2006260184B2 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
JP2020530435A (ja) Ｇｌｙ−Ｔβ４（Ｇｌｙ−チモシンβ４）を含有する眼球乾燥症の治療用薬学的組成物
US20170246176A1 (en) Phacosclerosis inhibitor
JP6910072B2 (ja) チモシンベータ４およびクエン酸を活性成分として含む角膜損傷予防／治療用組成物
HK40023769A (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
JP6634451B2 (ja) チモシンβ４を含有する組成物、およびそれを含む医薬製剤
JPH02193931A (ja) 角膜疾患治療用点眼剤
RU2277413C2 (ru) Способ лечения вторичной дистрофии роговицы
JP5087233B2 (ja) 角結膜障害の予防または治療剤
JP2004168697A (ja) 網膜疾患治療剤
JP2024528234A (ja) レコフラボン（ｒｅｃｏｆｌａｖｏｎｅ）を含有するドライアイ症候群を処置するための点眼組成物及びそれを製造するための方法
KR20170021667A (ko) 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230425